and/or

209 Press Releases found

Men with Metastatic Prostate Cancer Should Be Considered for Germline Genetic Testing of DNA Repair Genes

Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, University of Washington School of Medicine, University of Michigan, and the Institute of Cancer Research Royal Marsden Hospital.

  • Wednesday, July 6, 2016

MSK Researchers Hack the Metastatic Process Using Nanoparticles

Memorial Sloan Kettering Cancer Center (MSK) molecular pharmacologist Daniel Heller, PhD, and colleagues have identified a new strategy to target drugs specifically to cancer sites, including metastatic tumors. The approach involves nanoparticles designed to mimic a mechanism that tumors themselves use to metastasize throughout the body. This work, which will be featured on the cover of the June 29 issue of Science Translational Medicine, was applicable across a wide range of tumor and drug types and can potentially be applied to other conditions including vascular and autoimmune diseases.

  • Wednesday, June 29, 2016

Andrew L. Kung, MD, PhD, Named Chairman of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center

Andrew L. Kung, MD, PhD, has been named the new Chairman of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center (MSK). An accomplished physician, researcher, leader, and mentor, Dr. Kung most recently served as the Chief of the Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation at New York-Presbyterian/Morgan Stanley Children’s Hospital and Columbia University Medical Center (CUMC). Dr. Kung formally assumes his new role as Richard J. O’Reilly, MD, steps down as Chairman after more than 30 years.

  • Monday, June 20, 2016

Tri-Institutional Therapeutics Discovery Institute, Inc. Expands Partnership with Takeda Pharmaceutical Company, Ltd.

Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that they will expand the focus of the successful Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a partnership established in 2013 to expedite early-stage drug discovery of innovative new therapies. Under this expansion, Tri-I TDI will extend its current relationship with its industry partner, Takeda Pharmaceutical Company, Ltd. from the realm of small molecule discovery into the new research area of antibody drug discovery. All three institutions will benefit from Tri-I TDI’s expansion.

  • Thursday, June 16, 2016

ASCO 2016: Novel Targeted Drug Shows Promise Against Advanced Small Cell Lung Cancer

The experimental “smart-bomb” drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer, according to results from a first-in-human clinical trial to be presented today by a MSK researcher at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.

  • Sunday, June 5, 2016

Despite Pressing Need, Survey Finds Most Americans Unlikely to Enroll in Clinical Trials

The lack of participation in clinical research may be the Achilles’ heel of today’s cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of Memorial Sloan Kettering Cancer Center (MSK), only 35 percent of Americans indicated that they were “likely” to enroll in a clinical trial. Other studies have shown that only 4 percent of cancer patients enroll in clinical trials nationally each year.

  • Monday, May 23, 2016

Memorial Sloan Kettering Expands into Northern New Jersey

Memorial Sloan Kettering Cancer Center (MSK) will further enhance its ability to offer top cancer care to even more patients with the establishment of a freestanding, state-of-the-art outpatient treatment center in Bergen County, New Jersey. Residents from communities across northern New Jersey and southern New York State will have easier access to MSK’s unique expertise when MSK Bergen becomes fully operational in winter 2017.

  • Tuesday, May 10, 2016

Richard J. O’Reilly, MD, Named The Society of Memorial Sloan Kettering’s Inaugural Prize Winner for Groundbreaking Contributions in Pediatric Oncology

The Society of Memorial Sloan Kettering Cancer Center (MSK) has announced that Richard J. O’Reilly, MD, has been named the inaugural recipient of The Society of Memorial Sloan Kettering Prize. This new award recognizes an individual who has made outstanding contributions to the field of pediatric oncology.

  • Monday, May 2, 2016

Memorial Sloan Kettering Researcher’s Promising Entrectinib Clinical Trial Data Highlighted at American Association for Cancer Research Annual Meeting

Encouraging clinical trial data from Memorial Sloan Kettering Cancer Center (MSK) will be featured in this year’s American Association for Cancer Research (AACR) Annual Meeting press program and presented as part of the Precision Medicine Early Clinical Trial Plenary Session.

  • Sunday, April 17, 2016

Memorial Sloan Kettering Launches Teen and Young Adult Program and Opens The Lounge in Collaboration with Teen Cancer America and Who Cares

Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of its new Teen and Young Adult (TYA) Program, TYA  @  MSK, which will offer special services to MSK’s TYA population. In tandem, MSK officially opened The Lounge, a space designed especially for this unique age group that was made possible by a $1 million donation from Teen Cancer America. The nonprofit organization, co-founded by Roger Daltrey and Pete Townshend of The Who, partners with hospitals throughout the United States to develop specialized facilities for teens and young adults with cancer.

  • Friday, March 18, 2016